pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Avidity Biosciences, Inc., the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention S&P TMI Index, all published on March 3, 2026.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about S&P TMI Index
pharma is the sole category represented across all 1 tracked stories. Of the tracked stories, 1 of 1 also mention Avidity Biosciences, Inc., the most common co-covered peer. Each carries 2 original sources on average. We currently track 1 Biotech story that mention S&P TMI Index, all published on March 3, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 4 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering S&P TMI Index. Shared-story counts are live from our verified record — not editorial picks.
Avidity Biosciences (RNAM) has been removed from the S&P Global BMI and S&P TMI indices as part of a periodic rebalancing. The exclusion from these broad market benchmarks is expected to trigger mandatory selling by passive investment funds and ETFs tracking the indices.